WID’s Tom Turng envisions a future in which surgeons can order mass-produced artificial blood vessels that arrive ready to use in bypass surgeries.
WID seeks to add to its roster of excellent faculty with two new hires in emerging cutting-edge fields.
WID’s new hubs—Data Science, Multi-Omics, and Illuminating Discovery—represent a new path forward for collaborative research projects and fields.
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
Biomedical engineering professor and Discovery Fellow Kristyn Masters and colleagues identified the early stages of a process that may eventually cause aortic stenosis, a severe narrowing of the aortic valve that reduces blood flow to the body and weakens the heart.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
Understanding diversity in microbial communities and their role in infectious disease; in particular, the genetic basis for stability of microbial communities, the role of a gut community as a source of opportunistic pathogens, and the soil microbial community as a source of new antibiotics and antibiotic resistance genes.
Investigating how living organisms cooperate or compete in diverse and changing environments. Methods and perspectives are drawn from many fields, including ecology, evolution, molecular biology, physics, chemistry, engineering, mathematics, and computer science. The lab uses data-driven mechanistic and statistical models to predict when microbes or other organisms will persist or perish, with a broad goal of promoting human health through effective management of microbe-host interactions.
By bringing together stem cell biology, genome engineering, and biomaterials expertise, the Saha lab generates new tools for use with human-induced pluripotent stem cells to ask unique questions about human biology and disease.
Prof. Gong’s research group focuses on the design, synthesis/fabrication, and characterization of novel materials and devices. Many of their ongoing projects are multidisciplinary, bridging engineering with materials science, chemistry, and life sciences. Some of their efforts include multifunctional drug/agent nanocarriers for the combined delivery of therapeutic and diagnostic agents which can be used to treat and diagnose various types of diseases. Her group also studies multifunctional polymer nanocomposites for various applications including flexible electronics, supercapacitors, and nanogenerators.
The Ashton Group is working to understand, model, and recapitulate in vitro the instructive signals utilized by human embryos to pattern tissue-specific differentiation of pluripotent stem cells, and apply this knowledge towards the rational design of tissue engineered scaffolds and other regenerative therapeutic strategies.